Our findings showed that the high expression of RRM2 in HCC was closely related to PD1, PD-L1, and CTLA-4, suggesting that tumor immune escape may be involved in RRM2-mediated hepatocarcinogenesis, and RRM2 may be a synergistic therapeutic target related to immunotherapy in HCC. The gene discussed is RRM2; the disease is hepatocellular carcinoma.